Genomics & Precision Medicine Penny Stocks

US-listed genomics and precision-medicine penny stocks priced $0.50 to $5, ranked by today's percentage change. Gene editing, gene therapy, sequencing technology, liquid biopsy, companion diagnostics, and precision-medicine platforms. Updated intraday.

Data as of 5/30/2026 11:36:46 PM · Intraday prices · 57 penny stocks in theme
#SymbolCompanySectorPriceDay ChgVolume
1TNYATenaya Therapeutics, Inc. Common StockHealthcare$0.8816+10.35%5.1M
2MBIOMustang Bio, Inc.Healthcare$0.6731+6.17%41K
3XCURExicure, Inc. Common StockHealthcare$3.1500+6.06%15K
4SANASana Biotechnology, Inc. Common StockHealthcare$3.3150+5.91%5.0M
5NAUTNautilus Biotechnolgy, Inc. Common StockHealthcare$2.7300+5.00%545K
6PRMEPrime Medicine, Inc. Common StockHealthcare$3.5600+4.71%3.3M
7IRDOpus Genetics, Inc. Common StockHealthcare$4.3700+4.05%977K
8MXCTMaxCyte, Inc. Common StockHealthcare$1.2100+3.42%1.3M
9AVXLAnavex Life SciencesHealthcare$3.0400+3.40%1.3M
10ENGNenGene Therapeutics Inc. Common StockHealthcare$1.8400+3.37%1.1M
11CDIOCardio Diagnostics Holdings Inc. Common stockHealthcare$1.8600+3.16%60K
12OPKOpko Health Inc.Healthcare$1.4600+2.10%2.9M
13LNAILunai Bioworks Inc. Common StockHealthcare$3.1000+1.97%135K
14CRBUCaribou Biosciences, Inc. Common StockHealthcare$2.3500+1.73%1.4M
15PACBPacific Biosciences of California, Inc.Healthcare$1.4950+1.70%7.0M
16CTKBCytek Biosciences, Inc. Common StockHealthcare$4.1900+1.70%1.0M
17RCKTRocket Pharmaceuticals, Inc. Common StockHealthcare$3.0700+1.66%2.3M
18INOInovio Pharmaceuticals, Inc.Healthcare$1.3200+1.54%1.2M
19LABStandard BioTools Inc. Common StockHealthcare$1.1550+1.32%7.0M
20PRQRProQR Therapeutics N.V. Ordinary SharesHealthcare$1.5900+1.27%685K
21TCRXTScan Therapeutics, Inc. Common StockHealthcare$1.0900+0.93%208K
22CABACabaletta Bio, Inc. Common StockHealthcare$3.7950+0.66%2.5M
23BCDABioCardia, Inc. Common StockHealthcare$0.9214+0.50%101K
24FHTXFoghorn Therapeutics Inc. Common StockHealthcare$4.2850+0.35%105K
25QTRXQuanterix Corporation Common StockHealthcare$3.0600+0.33%812K
26EDITEditas Medicine, Inc. Common StockHealthcare$3.4400+0.29%3.9M
27PRLDPrelude Therapeutics IncorporatedHealthcare$3.93000.00%288K
28BNGOBionano Genomics, Inc. Common StockHealthcare$1.25000.00%184K
29GNLXGenelux Corporation Common StockHealthcare$3.07000.00%115K
30SERASera Prognostics, Inc. Class A Common StockHealthcare$2.14000.00%35K
31ALLRAllarity Therapeutics, Inc. Common StockHealthcare$1.6600-0.60%215K
32ACRVAcrivon Therapeutics, Inc. Common StockHealthcare$1.6200-0.61%367K
33OABIOmniAb, Inc. Common StockHealthcare$2.7000-0.74%456K
34VYGRVoyager Therapeutics, Inc. Common StockHealthcare$3.8700-0.77%448K
35QSIQuantum-Si Incorporated Class A Common StockHealthcare$1.1900-0.83%7.3M
36IBIOiBio, Inc. Common StockHealthcare$1.9050-1.30%324K
37CBUSCibus, Inc. Class A Common StockHealthcare$1.4250-1.72%217K
38MDXHMDxHealth SA Ordinary SharesHealthcare$0.7400-1.86%491K
39GNPXGenprex, Inc. Common StockHealthcare$0.7798-1.87%271K
40XGNExagen Inc. Common StockHealthcare$4.9750-2.07%353K
41SEERSeer, Inc. Class A Common StockHealthcare$1.8900-2.07%215K
42OCGNOcugen, Inc. Common StockHealthcare$1.3800-2.13%12.7M
43PHIOPhio Pharmaceuticals Corp. Common StockHealthcare$1.1150-2.19%108K
44CAMPCAMP4 Therapeutics Corporation Common StockHealthcare$4.3800-2.45%51K
45ALLOAllogene Therapeutics, Inc. Common StockHealthcare$2.1900-2.67%10.3M
46MGXMetagenomi Therapeutics, Inc. Common StockHealthcare$1.3600-2.86%188K
47ACIUAC Immune SAHealthcare$2.6550-3.45%293K
48PGENPrecigen, Inc. Common StockHealthcare$4.3400-3.77%5.5M
49ALPSALPS Group Inc Ordinary ShareHealthcare$0.7331-4.79%16K
50MYGNMyriad Genetics IncHealthcare$4.0100-4.98%6.0M

How Genomics Penny Stocks Trade

Genomics at sub-$5 is a mix of gene-editing platforms (CRISPR, base/prime editing, ZFNs), gene therapy specialists, sequencing-tool makers, and diagnostics companies. Like oncology, the trading is catalyst-driven — clinical readouts, FDA actions, and competitive technology announcements move individual names sharply.

  • Editing technology approach: CRISPR-Cas9, base editing, prime editing, and ZFN platforms have different IP, safety profiles, and timelines. Don't aggregate.
  • Gene therapy reimbursement: approved gene therapies cost $1M-$3M per patient. Payer adoption shapes commercial trajectory.
  • Sequencing instrument cycles: sequencing-tool plays trade with the Illumina/Element/etc. competitive landscape.
  • FDA novel-modality posture: the agency's evolving framework for gene/cell therapies affects approval timelines.
  • IP litigation: the CRISPR patent landscape has had years of litigation. Court rulings move names that depend on specific IP positions.
  • Manufacturing scale: gene therapies require specialized manufacturing. Companies with internal capacity trade at premiums to outsourced models.
  • Rare disease focus: orphan indications get faster approvals and pricing power but smaller markets. Trade-offs to weigh.
  • Dilution profile: like other clinical-stage biotechs, sub-$5 genomics names raise capital frequently — see our dilution explainer.

See also: biotech penny stocks (broader), oncology penny stocks, penny stocks under $1.